Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06725550 · ClinicalTrials.gov registry record · NA

Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

A NA study of Pain and Sickle Cell Disease, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06725550: Recruiting NA study of Pain and Sickle Cell Disease, sponsored by Indiana University.

NCT06725550 is a NA study of Pain and Sickle Cell Disease that is actively recruiting participants, run by Indiana University. The registered enrollment target is 120 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06725550, a NA study of Pain and Sickle Cell Disease, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

Primary Outcome

Characteristics of functional brain activity will be studied using fMRI.

Interventions

  • DEVICE needling acupuncture
  • DEVICE laser acupuncture

Study Locations (1)

Indiana

  • Indiana University School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-08-25
Est. Completion 2030-08-30
Phase NA
Indiana University

890 total trials

What NCT06725550 shows while recruiting

NCT06725550 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (61% lower).

The record links to 8 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which needling acupuncture is the first listed.

NCT06725550 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06725550 about?

NCT06725550 is a clinical study titled "Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0". The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

What is the current status of trial NCT06725550?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-08-25. Estimated completion is 2030-08-30.

What conditions does trial NCT06725550 study?

This clinical trial studies the following conditions: Pain, Sickle Cell Disease, Magnetic Resonance Imaging, Acupuncture, Electroencephalography.

What interventions are being tested in trial NCT06725550?

The interventions under investigation include: needling acupuncture (DEVICE), laser acupuncture (DEVICE).

Who is sponsoring clinical trial NCT06725550?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06725550 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06725550's enrollment target sits among peer trials

120 135th of 374 higher than 229 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06725550, the US trial registry maintained by the National Library of Medicine. NCT06725550 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.